Axsome Therapeutics News

Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment?

Simply Wall StOct 30 21:27

Axsome Therapeutics Presents Data From Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

GlobeNewswireOct 29 19:00

Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral

Seeking AlphaOct 22 02:52

Positive Buy Recommendation for Axsome Therapeutics Driven by Promising AXS-05 Efficacy in Alzheimer's Agitation

TipRanksOct 21 19:16

Strong Commercial Performance and Growth Potential Drive Buy Rating for Axsome Therapeutics' Auvelity

TipRanksOct 21 18:26 · Ratings

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

GlobeNewswireOct 15 19:00

Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115

Futu NewsOct 12 21:31 · Ratings

Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $106

Futu NewsOct 9 06:31 · Ratings

Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views

BenzingaOct 5 02:08

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesOct 5 00:17 · Ratings

RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating

MT NewswiresOct 4 19:42 · Ratings

The Five-year Returns Have Been Enviable for Axsome Therapeutics (NASDAQ:AXSM) Shareholders Despite Underlying Losses Increasing

Simply Wall StOct 3 21:13

Express News | Axsome Therapeutics: Fifth Amendment to Increase Tranche 3 Commitment From $75 to $80 Mln

BreakingsOct 2 05:28

Express News | Axsome Therapeutics: On September 30 Entered Into Fifth Amendment to Its Loan & Security Agreement Dated Sept 25, 2020

BreakingsOct 2 05:28

Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140

Futu NewsOct 1 19:31 · Ratings

Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes

TipRanksOct 1 18:55 · Ratings

Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating

Futu NewsSep 28 02:32 · Ratings

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)

TipRanksSep 28 01:50 · Ratings

Axsome Therapeutics Presents Data From Multiple Programs at Sleep Europe 2024

GlobeNewswireSep 24 19:00

Axsome Therapeutics: A Strong Buy on Auvelity's Robust Market Performance and Growth Prospects

TipRanksSep 22 21:45